主要從事分子靶向抗腫瘤藥物特別是靶向PI3K/mTOR通路和腫瘤免疫調(diào)控創(chuàng)新藥物的研究與開(kāi)發(fā)，開(kāi)展從藥物研發(fā)、機(jī)制探討和生物標(biāo)志物探尋一體化的藥物研究。作為藥理團(tuán)隊(duì)負(fù)責(zé)人研發(fā)的1.1類新藥處于國(guó)際II期臨床試驗(yàn)。在STTT，Cancer Res等國(guó)際學(xué)術(shù)期刊發(fā)表SCI 論文90余篇，SCI 他引3000余次，獲國(guó)內(nèi)外專利授權(quán)37項(xiàng)。獲得國(guó)家自然科學(xué)二等獎(jiǎng)、上海市自然科學(xué)一等獎(jiǎng)（均為第三完成人）等學(xué)術(shù)獎(jiǎng)勵(lì)
分子靶向抗腫瘤藥物特別是靶向PI3K/mTOR通路和腫瘤免疫調(diào)控創(chuàng)新藥物的研究與開(kāi)發(fā)以及相關(guān)治療學(xué)研究
2013年藥明康德生命化學(xué)研究獎(jiǎng)???
2011年明治生命科學(xué)獎(jiǎng)-科學(xué)獎(jiǎng)
2011年上海市第七屆巾幗創(chuàng)新獎(jiǎng)??
2010年賽諾菲 安萬(wàn)特-中國(guó)科學(xué)院上海生命科學(xué)研究院優(yōu)秀青年人才獎(jiǎng)
2009年國(guó)家自然科學(xué)二等獎(jiǎng)（排名第三）???
2008年中國(guó)藥理學(xué)會(huì)施維雅青年藥理學(xué)工作者獎(jiǎng)???
2007年上海市自然科學(xué)獎(jiǎng)一等獎(jiǎng)（排名第三）???
2005年上海首屆藥學(xué)科技獎(jiǎng)一等獎(jiǎng) （排名第三）???
2005年AACR-Scholar-in-Training Award??
2004年AACR-Scholar-in-Training Award
2008、2012、2014、2018、2020、2022年 獲國(guó)家自然科學(xué)基金面上項(xiàng)目支持?
2017、2019年 獲中國(guó)科學(xué)院戰(zhàn)略性先導(dǎo)專項(xiàng)“個(gè)性化藥物--基于疾病分子分型的普惠新藥研究”支持???
2008、2018年 獲新藥創(chuàng)制重大專項(xiàng)支持???
2008、2014 獲上海市科委重點(diǎn)項(xiàng)目支持???
2008-2016作為研究骨干獲國(guó)家自然科學(xué)基金創(chuàng)新研究群體基金支持???
2008 獲上海市浦江人才計(jì)劃支持
1.Sun YL,? Chen MM,? Han YY,? Li? WQ,? Ma XY,? Shi ZH, Zhou Y,? Xu? L, Yu L, Wang YX, Yu JY, Diao XX4 ,?Meng LH*,? Xu SL*.? Discovery of Pyrido[2,3- d]pyrimidin-7-one Derivatives as Highly Potent and Efficacious Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Inhibitors for Cancer Treatment.?J Med Chem?2024 Feb 22. doi: 10.1021/acs.jmedchem.3c02288.
2.Zhang X, Wang YX, Zhang X, Shen YY, Yang K, Ma QY, Qiao YM, Shi JJ, Wang Y, Xu L Yang BY, Ge GX, Hu LD, Kong XY, Yang CH, Chen Y*, Ding J*,?Meng LH*. Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kα inhibitors.?Signal Transduct Target Ther. 2023;8(1):153.
3.Chen MM, Guo W, Chen SM, Guo XZ, Xu L, Ma XY, Wang YX, Xie C,?Meng LH*. Xanthine dehydrogenase rewires metabolism and the survival of nutrient deprived lung adenocarcinoma cells by facilitating UPR and autophagic degradation.?Int J Biol Sci?2023;19(3):772-788.
4.Xing H, Gao MS, Wang YX, Zhang X, Shi J, Wang X, Liu X, Ma Q, Kong X, Yang C, Ding J*,?Meng L*. Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3Kα inhibitors in esophageal squamous cell carcinoma.?Clin Transl Med.?2022;12:e835
5.Zhang X, Wang YX,?Meng L*. Comparative genomic analysis of esophageal squamous cell carcinoma and adenocarcinoma: New opportunities towards molecularly targeted therapy.?Acta Pharmaceutica Sinica B. 2022; 12( 3): 1054-1067
6.Chen ZQ, Cao ZR, Wang Y, Zhang X, Xu L, Wang YX, Chen Y, Yang CH, Ding J*,?Meng LH*. Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma.?Cancer Lett.?2022 ;524:206-218.
7.Sun P, Zhang X, Wang RJ, Ma QY, Xu L, Wang Y, Liao HP, Wang HL, Hu LD, Kong X*, Ding J*,?Meng LH*. PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8 + T cells and promoting fatty acid metabolism.?J Immunother Cancer. 2021; 9(8):e003093.?
8.Wang YX, Zhang X, Ma QY, Hu LD, Zhang X, Wang Y, Xu L, Yang CH, Tan C, Kong XY, Ding J*,?Meng LH*. Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cell.?Cell Death Dis. 2021;12(1):85.?
9.Liu XL, Wang BB, Wang Y, Wang YX, Yang CH, Tan C, Zhang X, He QJ, Ding J*,?Meng LH*. Unbiased screening reveals that blocking exportin 1 overcomes resistance to PI3Kα inhibition in breast cancer.?Signal Transduct Target Ther.?2019 Nov 22;4:49.
10.Shi JJ, Xing H, Wang YX , Zhang X, Zhan QM, Geng MY, Ding J*,?Meng LH*. PI3Kα Inhibitors Sensitize Esophageal Squamous Cell Carcinoma to Radiation by Abrogating Survival Signals in Tumor Cells and Tumor Microenvironment.?Cancer Lett.?2019;459:145-155
